{
  "docId": "019de076-8183-75b8-8b2d-7503ba8c42ba",
  "docSlug": "f8cc3498a347f12db8c194c5955f1d44",
  "documentTitle": "Kymera | Investor Presentation Deck | 46 slides",
  "authorId": "kymera",
  "authorName": "Kymera Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 46,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes PK/PD correlation, blood IRAK4 levels, skin exposure, and skin lesion IRAK4 reduction data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8183-75b8-8b2d-7503ba8c42ba/12",
  "deckHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba",
  "deckJsonHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba.json",
  "deckAnchorHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.35,
        "y": 0.7
      },
      "kind": "callout",
      "text": "HS and AD Patients IRAK4 Levels at Day 28 (n=4) near LLOQ",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34ef730e-d530-431e-a501-5ec55905d645",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "callout",
      "text": "KT-474 concentrations in plasma lead to same level of IRAK4 degradation in HV (n=48) and HS/AD (n=20) patients. Concentrations above 3 ng/mL lead to same level of degradation (>80%) in HV and Patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9800f49f-19e8-4cba-9e3d-f27aa0ef58ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.6,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Reduced IRAK4 in Skin Lesions of AD and HS Patients",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f03f790-093d-4889-8c88-58be7c411a53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.6,
        "y": 0.15
      },
      "kind": "chart",
      "text": "High KT-474 Exposure in HS and AD Patients Skin",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47e62779-22cc-4186-85cf-7c7f68d0768d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.2,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "chart",
      "text": "IRAK4 Levels in Blood (PBMC) in Patients at Day 28 (MS)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c74f6fbe-b60b-4e37-b623-8d351ef1225d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "PK/PD Correlation in Blood (Plasma/Monocytes) (FLOW)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2604d6ff-8a50-41a4-9e2e-4e36daeee01f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-474 Plasma PK and IRAK4 Degradation in HS and AD Patients Dosed for 28 Days are Comparable to HV",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f5100cb-095f-474e-94bf-68a909b0a1bf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "1809a2a6-5c00-455c-a1d6-79b90675926d",
      "evidence": "The slide presents a waterfall chart showing IRAK4 levels",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "3821b163-197d-4c86-9367-33b4bd3fb93a",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The deck showcases the potential for broad activity across multiple diseases, creating desire for Kymera's TPD approach.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "7b376215-a5b5-4891-ad20-1901edfeffd7",
      "evidence": "The deck presents a clear logical chain from the problem to the solution and potential benefits.",
      "position": 0,
      "objective": "To demonstrate the logic and potential of Kymera's TPD approach",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4c55e1a3-cbe4-4bd4-91f4-d237841a6ee0",
      "evidence": "The deck implies the limitations of current treatments and the potential consequences of not adopting new approaches.",
      "position": 1,
      "objective": "To highlight the cost of inaction and the need for new treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}